In the United States, on July 6, 2026, Dr. Mehmet Oz, the CMS Administrator, expressed his support for GLP-1 medications during an exclusive interview at the Great American State Fair in Washington D.C. He highlighted the effectiveness of these drugs, such as Ozempic, in addressing obesity, high blood pressure, and diabetes. Dr. Oz emphasized that while these medications are not substitutes for diet and exercise, they can help individuals who struggle with weight loss due to various health issues, including joint pain and internal dysfunction.
Dr. Oz announced the launch of the Medicare GLP-1 Bridge program, which aims to provide access to GLP-1 drugs for seniors at a cost of $50 per month, contingent on meeting specific health criteria and obtaining prior authorization from a healthcare provider. This initiative is particularly significant for overweight individuals who do not have conditions like high blood pressure or diabetes, as they typically do not qualify for these medications under current guidelines.
The CMS Administrator projected that the use of GLP-1 drugs could lead to substantial savings for taxpayers by reducing the prevalence of chronic conditions, which he noted account for approximately 70% of healthcare spending in the U.S. Dr. Oz stated that obesity is the primary driver of these costs, making the promotion of GLP-1 medications a strategic decision for improving public health and reducing healthcare expenditures.
Despite the potential benefits, Dr. Oz cautioned that there is no single solution to obesity and chronic diseases. He acknowledged the importance of combining medication with foundational health practices, such as diet and exercise, to achieve lasting results. He also expressed a desire to eliminate the stigma associated with obesity, emphasizing that weight management is complex and influenced by various factors unique to each individual.
